自體免疫疾病治療市場（按治療類型、疾病類型、給藥途徑、治療用途和最終用戶分類）—2025-2032 年全球預測

預計到 2032 年，自體免疫疾病治療市場將成長至 3,963.2 億美元，複合年成長率為 7.96%。

主要市場統計數據
基準年2024年	2146.5億美元
預計2025年	2311.5億美元
預測年份：2032年	3963.2億美元
複合年成長率（%）	7.96%

簡潔的策略介紹，概述自體免疫療法的臨床挑戰、商業性現實和相關人員協調

自體免疫治療領域的特點是科學進步日新月異、監管環境複雜多變以及付款人預期不斷變化，所有這些都影響著開發人員和投資者的策略選擇。在這種環境下，一份簡潔、將臨床需求與商業性現實相結合的介紹，對於準備優先考慮產品線、分配資金以及與外部合作夥伴合作的經營團隊至關重要。

本節概述了尚未滿足的臨床需求、精準生技藥品和小分子藥物的加速發展作用，以及與製造、低溫運輸物流和真實世界證據生成相關的營運挑戰，為本文奠定了基礎。本部分也強調了臨床試驗設計與長期價值創造之間的相互關係，並強調了與關鍵相關人員（包括臨床醫生、付款人和專業藥房）進行早期合作的重要性。過渡性洞察重點介紹了近期創新可能與系統性限制因素相交的地方，為後續更深入的分析提供了實踐基礎。

科學、商業性和營運創新將如何融合，重塑自體免疫疾病治療的臨床策略和商業化路徑

科學、技術和政策的變革性轉變正在重新定義自體免疫疾病的診斷、治療和管理方式，其影響波及整個價值鏈。生物治療方法的進步、標靶小分子化學型的改進以及精準免疫調節方法的日益成熟，使得治療策略更加明確地專注於改變疾病進展並實現持久緩解，而非僅僅控制症狀。

同時，診斷技術的進步和生物標記主導的患者細分正在重塑臨床試驗隊列，並加速自適應試驗設計的發展。這種科學轉變伴隨著商業和商業性轉型，包括開發商之間垂直整合的加強、製造和分銷環節對戰略夥伴關係關係的更大依賴，以及對數位化醫療輔助設備在提高用藥依從性和監測安全性方面的日益成長的期望。這些變化迫使我們重新評估傳統的商業化策略，並制定將臨床差異化與可擴展製造和支付方證據要求相結合的整合策略。

評估不斷變化的關稅政策將如何影響自體免疫療法供應鏈的彈性、製造地決策和籌資策略

美國將於2025年生效的新關稅及相關貿易調整將對自體免疫治療供應鏈、成本結構和產業計畫產生多方面的影響。這些措施不僅會影響上游的原料藥成分和生物製藥材料的採購，還會影響下游的最終組裝、填充和封口操作以及低溫運輸物流的地點決策。因此，企業正在重新評估籌資策略，以保持供應的連續性，同時降低進口成本上升的風險。

為了應對這種情況，許多相關人員正在推行近岸外包和區域化策略，以減少運輸時間和監管摩擦，從而導致臨床材料和商業庫存的前置作業時間發生變化。委託製造製造商和經銷商正在重新協商業務條款，以適應營運複雜性並確保服務水準的連續性。從策略角度來看，這些動態凸顯了供應鏈彈性、多元化供應商網路以及將關稅敏感性分析納入監管提交時間表和臨床開發預算的情境規劃的重要性。最終，積極調整採購和製造佈局的組織將更有能力維護患者的用藥管道並保護治療利潤。

將治療方式、適應症、給藥途徑、治療意圖和護理環境與開發和商業化需求聯繫起來的全面細分分析

細緻的細分框架揭示了治療方式、適應症、給藥途徑、治療意圖和最終用戶環境如何影響開發重點和商業化策略。治療類別涵蓋多種模式，包括生物製藥（如抗高血糖藥、融合蛋白、基因療法和單株抗體），以及細胞激素抑制劑、免疫調節劑、免疫抑制劑、非類固醇消炎劑、磷酸二酯酶抑制劑、皮質類固醇和小分子（包括JAK抑制劑）。每個類別的開發挑戰、監管證據預期和製造考量都會影響臨床時間和價值敘述。

疾病類型包括發炎性腸道疾病、紅斑性狼瘡、多發性硬化症、牛皮癬、類風濕性關節炎和第 1 型糖尿病。這種適應症的分佈導致終點選擇、試驗持續時間和患者招募複雜性的異質性。給藥途徑主要分為注射療法和口服療法，注射療法又分為肌肉注射、靜脈注射和皮下注射。這些因素直接影響病患偏好、依從性模式和上市時所需的支援服務類型。治療應用目標各不相同，包括改變疾病進展、調節免疫系統、控制疼痛和減輕炎症，每個目標都需要量身定做的臨床方案和差異化的通訊。最終使用者包括門診手術中心、醫院和研究機構，這些環境決定了採購流程、處方定位和上市後證據收集的速度。整合這些細分維度使開發人員能夠優先考慮與內部能力和外部訪問一致的適應症和模式，同時使付款人和提供者能夠更好地預測哪些治療方法在個人醫療保健環境中提供最引人注目的價值提案。

區域策略對美洲、中東和非洲以及亞太地區不同管理體制、付款人模式和臨床實踐模式的影響

區域動態對於策略規劃至關重要，因為不同地區的監管要求、付款人架構和臨床實踐模式差異巨大。美洲地區高度重視基於價值的報銷途徑、針對突破性療法的加速監管項目，以及影響上市順序和簽約策略的龐大專業藥房網路和一體化配送網路。這種環境有利於強力的真實世界證據項目以及與付款人的早期合作，以確保藥物的可及性和報銷結果。

在歐洲、中東和非洲，市場進入方式多種多樣，涉及不同程度的深入評估和針對特定國家的價格談判，因此必須與衛生技術評估預期和當地臨床指南保持一致。在該地區，能夠明顯抵消成本並帶來長期效益的治療方法往往更受青睞。在亞太地區，醫療保健體系發達的國家正迅速採用創新治療方法，而其他面臨公共預算限制的國家則正在採用分級准入策略。在這些市場中，彈性價格設定模式、與當地製造商的合作以及量身定做的臨床開發計劃可以加速治療方法的採用。在所有地區，跨境監管協調工作和不斷發展的數位基礎設施將繼續影響臨床開發和商業化的策略選擇。

透過結合科學創新、製造管理和證據產生能力，實現差異化的關鍵競爭和夥伴關係動態

領先研發公司、受託製造和服務供應商之間的競爭動態正日益受到策略聯盟、垂直整合和定向收購的影響，這些舉措有助於提升生產規模和科研能力。擁有深厚生技藥品專業知識和單株抗體、融合蛋白和基因治療藥物專有平台的公司正在透過將臨床差異化與生產控制相結合來追求差異化定位，從而降低上市時間風險並增強品質保證。同時，規模較小、更敏捷的創新者正在利用夥伴關係關係來推進專用分子和利基適應症的開發，通常專注於伴隨診斷和患者分層。

能夠證明低溫運輸可靠性、靈活生產能力和合規性的契約製造和物流供應商，正成為尋求最大限度減少供應中斷的開發商事實上的推廣合作夥伴。此外，投資於強力的真實世界證據生成和患者支持項目的組織，能夠增強其與付款人和醫療保健提供者的談判地位。這些策略舉措有利於那些能夠將科學新穎性和付款人相關證據產生相結合的公司，從而為那些能夠協調端到端開發和商業化路徑的公司提供競爭優勢。

可行的策略建議，以協調臨床開發、供應鏈彈性和市場準備，從而加速患者獲取藥物並獲得商業性成功

產業領導者應優先考慮一系列切實可行的措施，以解決臨床差異化、供應鏈韌性和市場進入準備等問題。首先，應將早期臨床開發與付款方證據要求相協調，積極與監管機構溝通，並降低關鍵試驗設計和終點選擇的風險。投資生物標記主導的患者分層和自適應測試方法可以縮短開發週期並增強價值檔案。其次，應實現供應商網路多元化，並考慮建立區域製造和策略夥伴關係，以降低關稅和物流波動的影響。

第三，制定全面的打入市場策略，將臨床效益與營運支援服務（例如病患援助、依從性計畫和數位健康工具）結合，從而改善療效並降低總護理成本。第四，與製造外包、分銷合作夥伴和臨床研究機構建立有針對性的合作夥伴關係，以確保在關鍵曲折點具備能力和專業知識。最後，將真實世界證據計畫納入開發路徑，以支持跨區域系統的報銷討論。透過對這些行動進行排序並將其與明確的里程碑聯繫起來，領導者可以降低執行風險並加快患者獲得藥物的速度。

一種透明、多方法的研究調查方法，結合專家訪談、監管分析、科學文獻綜述和供應鏈情境評估

本研究採用多種方法，結合定性專家訪談、監管和政策分析以及同行評審的科學文獻綜合分析，為策略決策建立了強力的依證。主要的定性資訊是透過與臨床研究人員、供應鏈高管、市場准入專家和付款人代表進行結構化訪談而獲得的。

二次分析仔細審查了監管指南、臨床試驗註冊和科學出版物，以檢驗特定治療模式的開發路徑和安全性。供應鍊和關稅影響評估是基於貿易流量數據和物流基準，並結合基於情境的敏感度檢查來識別弱點。調查方法和資料來源的透明度有助於可重複性和有針對性的後續分析。

結論性觀點將臨床前景與營運要求以及市場進入先決條件相結合，以實現對患者產生有意義的影響

總而言之，自體免疫治療領域正處於曲折點，科學突破必須與營運規範和成熟的市場進入策略結合。先進生技藥品、標靶小分子藥物和精準醫療方法的融合為改變疾病發展軌跡提供了重要機遇，但要實現這一潛力，需要在臨床證據生成、生產可靠性和支付方參與等方面開展合作。

投資於韌性供應鏈、生物標記賦能開發以及一體化商業支援服務的領導者，將最有能力將治療前景轉化為永續的患者效益。隨著監管和貿易格局的演變，持續的情境規劃和積極的相關人員參與將成為區分哪些專案能夠實現廣泛應用，哪些專案面臨長期應用障礙的關鍵。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

• 針對 B 細胞和 T 細胞交互作用的雙特異性抗體在狼瘡治療中的出現
• 基於 CRISPR 的基因編輯療法推動類風濕性關節炎的個人化治療
• 擴大JAK抑制劑和生物製藥組合以增強乾癬治療的療效
• 以微生物組為重點的治療方法調節發炎性腸道疾病的腸道免疫途徑
• 真實世界證據平台的成長支持加速自體免疫藥物的核准
• 實施數位健康解決方案，監測患者在自體免疫疾病治療中的依從性和結果

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章自體免疫疾病治療市場（依治療類型）

• 抗高血糖藥物
• 生物製藥
  • 融合蛋白
  • 基因治療
  • 單株抗體
• 細胞激素抑制劑
• 免疫調節藥物
• 免疫抑制劑
• 非類固醇消炎劑（NSAID）
• 磷酸二酯酶抑制劑
• 小分子
  • 皮質類固醇
  • JAK抑制劑

第9章自體免疫疾病治療市場（依疾病類型）

• 發炎性腸道疾病
• 紅斑狼瘡
• 多發性硬化症
• 銀屑病
• 類風濕性關節炎
• 1型糖尿病

第10章自體免疫疾病藥物市場（依給藥途徑）

• 注射
  • 肌肉注射
  • 靜脈
  • 皮下
• 口服

第11章自體免疫疾病藥物市場（依治療應用）

• 疾病進展的變化
• 免疫系統調節
• 疼痛管理
• 減少炎症

第 12 章自體免疫疾病治療市場（按最終用戶）

• 門診手術中心
• 醫院
• 研究機構

第13章自體免疫疾病治療市場（按地區）

• 美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第14章自體免疫疾病藥物市場（依類別）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第15章 各國自體免疫疾病治療市場

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第16章競爭格局

• 2024年市佔率分析
• 2024年FPNV定位矩陣
• 競爭分析
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix Labs, LLC
  • bioMerieux SA
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Exagen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • UCB SA
  • Werfen SA

The Autoimmune Disease Therapeutics Market is projected to grow by USD 396.32 billion at a CAGR of 7.96% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 214.65 billion
Estimated Year [2025]	USD 231.15 billion
Forecast Year [2032]	USD 396.32 billion
CAGR (%)	7.96%

A concise strategic introduction framing clinical imperatives, commercial realities, and stakeholder alignment across the autoimmune therapeutics landscape

The autoimmune therapeutics landscape is characterized by rapid scientific progress, complex regulatory pathways, and evolving payer expectations that together shape strategic choices for developers and investors. In this environment, a concise introduction that harmonizes the clinical imperatives with commercial realities is essential for executive teams preparing to prioritize pipelines, allocate capital, and engage external partners.

This section sets the stage by outlining prevailing clinical unmet needs, the accelerating role of precision biologics and small molecule agents, and the operational challenges associated with manufacturing, cold chain logistics, and real-world evidence generation. It emphasizes the interplay between clinical trial design and long-term value creation, and it underscores the importance of early alignment with key stakeholders, including clinicians, payers, and specialty pharmacies. Transitional insights highlight where near-term innovations are likely to intersect with systemic constraints, providing a pragmatic foundation for the deeper analyses that follow

How scientific, commercial, and operational innovations converge to reshape clinical strategies and commercialization pathways in autoimmune disease treatment

Transformative shifts across science, technology, and policy are redefining how autoimmune diseases are diagnosed, treated, and managed, with implications that reverberate across the entire value chain. Advances in biologic modalities, improvements in targeted small molecule chemotypes, and maturation of precision immunomodulatory approaches are enabling therapeutic strategies that focus more explicitly on altering disease progression and achieving durable remission rather than merely managing symptoms.

Concurrently, diagnostic improvements and biomarker-driven patient segmentation are reshaping clinical trial cohorts and accelerating adaptive trial designs. These scientific shifts are complemented by commercial and operational transformations, including increased vertical integration among developers, greater reliance on strategic partnerships for manufacturing and distribution, and elevated expectations for digital health adjuncts that improve adherence and monitor safety. Together, these changes necessitate a re-evaluation of traditional commercialization playbooks and call for integrated strategies that align clinical differentiation with scalable manufacturing and payer evidence requirements

Assessing how evolving tariff policies influence supply chain resilience, manufacturing footprint decisions, and procurement strategies for autoimmune therapies

The introduction of new tariff measures and related trade adjustments in the United States in 2025 exerts multifaceted effects across supply chains, cost structures, and operational planning for autoimmune therapeutics. These measures influence upstream procurement of active pharmaceutical ingredients and biologic raw materials, as well as downstream decisions related to where to site final assembly, fill-finish operations, and cold chain logistics. As a result, companies are recalibrating sourcing strategies to mitigate exposure to elevated import costs while preserving supply continuity.

In response, many stakeholders are pursuing near-shoring and regionalization strategies to reduce transit times and regulatory friction, which in turn changes lead times for clinical supplies and commercial inventory. Contract manufacturers and distributors are renegotiating terms to absorb operational complexity and to ensure service level continuity. From a strategic perspective, these dynamics emphasize the importance of supply chain resilience, diversified supplier networks, and scenario planning that integrates tariff sensitivity analyses into regulatory submission timelines and clinical development budgets. Ultimately, organizations that proactively adapt their sourcing and manufacturing footprints will be better positioned to maintain patient access and to protect therapeutic margins

Comprehensive segmentation analysis that links modality, indication, administration route, therapeutic intent, and care setting to development and commercialization imperatives

A nuanced segmentation framework reveals how therapeutic modality, disease indication, administration route, therapeutic intent, and end-user environment jointly inform development priorities and commercialization tactics. Therapeutic types encompass a diverse set of modalities including Antihyperglycemics, Biologics such as Fusion Proteins, Gene Therapy, and Monoclonal Antibodies, Cytokine Inhibitors, Immunomodulators, Immunosuppressants, Nonsteroidal Anti-Inflammatory Drugs, Phosphodiesterase Inhibitors, and Small Molecules which further include Corticosteroids and JAK Inhibitors. Each class carries distinct development challenges, regulatory evidence expectations, and manufacturing considerations that influence time-to-clinic and value narratives.

Disease types range across Inflammatory Bowel Disease, Lupus Erythematosus, Multiple Sclerosis, Psoriasis, Rheumatoid Arthritis, and Type 1 Diabetes, and this distribution of indications drives heterogeneity in endpoint selection, trial duration, and patient recruitment complexity. Route of administration considerations split primarily between Injectable and Oral therapies, with injectable delivery further differentiated by intramuscular, intravenous, and subcutaneous approaches; these factors have direct implications for patient preference, adherence patterns, and the types of support services required at launch. Therapeutic application objectives span disease progression alteration, immune system modulation, pain management, and reduction of inflammation, each demanding tailored clinical programs and differentiated messaging. End-user contexts include ambulatory surgical centers, hospitals, and research institutes, and these settings dictate procurement processes, formulary positioning, and the cadence of post-market evidence collection. By synthesizing these segmentation dimensions, developers can prioritize indications and modalities that align with internal capabilities and external access realities, while payers and providers can better anticipate which therapeutic profiles will offer the most compelling value propositions in distinct care settings

Regional strategic implications tied to divergent regulatory regimes, payer models, and clinical practice patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics are critical to strategic planning because regulatory requirements, payer architectures, and clinical practice patterns diverge substantially across geographies. In the Americas, there is a concentrated emphasis on value-based reimbursement pathways, accelerated regulatory programs for breakthrough therapies, and an extensive network of specialty pharmacies and integrated delivery networks that influence launch sequencing and contracting strategies. This environment rewards robust real-world evidence programs and early payer engagement to secure access and reimbursement outcomes.

Europe, Middle East & Africa presents a mosaic of market access approaches, with varying degrees of centralized assessment and country-specific pricing negotiations; here, alignment with health technology assessment expectations and local clinical guidelines is essential. The region often favors therapeutic approaches that demonstrate clear cost-offsets and long-term benefits. Asia-Pacific markets exhibit rapid adoption of innovative therapies in certain high-capacity health systems, while other countries within the region are characterized by constrained public budgets and tiered access strategies. For these markets, flexible pricing models, partnerships with local manufacturers, and tailored clinical development plans can accelerate uptake. Across all regions, cross-border regulatory harmonization efforts and evolving digital infrastructure will continue to influence strategic choices for clinical development and commercialization

Key competitive and partnership dynamics that deliver differentiation through combined scientific innovation, manufacturing control, and evidence generation capabilities

Competitive dynamics among lead developers, contract manufacturing organizations, and service providers are increasingly shaped by strategic collaborations, vertical integration, and targeted acquisitions that unlock manufacturing scale and scientific capabilities. Companies with deep biologics expertise and proprietary platforms for monoclonal antibodies, fusion proteins, and gene therapies are pursuing differentiated positioning by coupling clinical differentiation with manufacturing control, thereby reducing time-to-market risk and enhancing quality assurance. At the same time, smaller, nimble innovators are leveraging partnerships to advance specialized molecules and niche indications, often focusing on companion diagnostics and patient stratification.

Contract manufacturing and logistics providers that can demonstrate cold chain reliability, flexible capacity, and regulatory compliance are becoming de facto extension partners for developers seeking to minimize supply disruptions. Additionally, organizations that invest in robust real-world evidence generation and patient support programs enhance their negotiating posture with payers and providers. These strategic moves collectively favor entities that can align scientific novelty with operational excellence and payer-relevant evidence generation, creating a competitive advantage for those able to orchestrate end-to-end development and commercialization pathways

Actionable strategic recommendations that align clinical development, supply chain resilience, and market access preparations to accelerate patient access and commercial success

Industry leaders should prioritize a set of pragmatic, actionable steps that address clinical differentiation, supply chain resilience, and market access readiness. First, align early clinical development with payer evidence requirements and engage with regulatory authorities proactively to de-risk pivotal trial design and endpoint selection. Investing in biomarker-driven patient stratification and adaptive trial methodologies can shorten development cycles and strengthen value dossiers. Second, diversify supplier networks and consider regionalized manufacturing or strategic partnerships to mitigate tariff and logistics volatility while maintaining quality compliance and reliable supply for clinical and commercial phases.

Third, design integrated go-to-market strategies that couple clinical benefits with operational support services such as patient assistance, adherence programs, and digital health tools that improve outcomes and reduce total cost of care. Fourth, pursue deliberate collaborations with contract manufacturers, distribution partners, and clinical research organizations to secure capacity and specialized capabilities at critical inflection points. Finally, embed real-world evidence planning into development pathways to support reimbursement discussions across diverse regional systems. By sequencing these actions and tying them to clear milestones, leaders can reduce execution risk and accelerate patient access

Transparent multi-method research methodology combining expert interviews, regulatory analysis, scientific literature review, and supply chain scenario assessments

This research integrates a multi-method approach that combines qualitative expert interviews, regulatory and policy analysis, and synthesis of peer-reviewed scientific literature to produce a robust evidence base for strategic decision-making. Primary qualitative inputs were obtained through structured interviews with clinical investigators, supply chain executives, market access specialists, and payer representatives, enabling triangulation of perspectives across the development and commercialization continuum.

Secondary analysis consisted of a careful review of regulatory guidance, clinical trial registries, and scientific publications to validate modality-specific development pathways and safety profiles. Supply chain and tariff impact assessments were constructed using trade flow data and logistics benchmarks, together with scenario-based sensitivity checks to identify points of vulnerability. Throughout the methodology, cross-validation exercises ensured that conclusions were grounded in observable trends and expert judgment rather than speculation, and transparency around data sources and assumptions supports reproducibility and targeted follow-up analyses

Concluding perspective that synthesizes clinical promise with operational imperatives and market access prerequisites for meaningful patient impact

In conclusion, the autoimmune therapeutics arena is at an inflection point where scientific breakthroughs must be matched with disciplined operational execution and sophisticated market access strategies. The convergence of advanced biologics, targeted small molecules, and precision medicine approaches presents substantial opportunity to alter disease trajectories, but realizing that potential requires alignment across clinical evidence generation, manufacturing reliability, and payer engagement.

Leaders that invest in resilient supply chains, biomarker-enabled development, and integrated commercial support services will be best positioned to transform therapeutic promise into sustainable patient impact. As regulatory and trade landscapes evolve, continuous scenario planning and proactive stakeholder alignment will serve as the differentiating factors between programs that achieve broad access and those that face protracted adoption hurdles

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Emergence of bispecific antibodies targeting B cell and T cell interactions in lupus treatment
• 5.2. CRISPR-based gene editing therapeutics advancing personalized treatment for rheumatoid arthritis
• 5.3. Expansion of JAK inhibitor combinations with biologics to enhance efficacy in psoriasis management
• 5.4. Microbiome-focused therapies modulating gut immune pathways in inflammatory bowel disease
• 5.5. Growth of real-world evidence platforms supporting accelerated approval for autoimmune drugs
• 5.6. Adoption of digital health solutions to monitor patient adherence and outcomes in autoimmune care

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Autoimmune Disease Therapeutics Market, by Therapeutic Types

• 8.1. Antihyperglycemics
• 8.2. Biologics
  • 8.2.1. Fusion Proteins
  • 8.2.2. Gene Therapy
  • 8.2.3. Monoclonal Antibodies
• 8.3. Cytokine Inhibitors
• 8.4. Immunomodulators
• 8.5. Immunosuppressants
• 8.6. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• 8.7. Phosphodiesterase Inhibitors
• 8.8. Small Molecules
  • 8.8.1. Corticosteroids
  • 8.8.2. JAK Inhibitors

9. Autoimmune Disease Therapeutics Market, by Disease Type

• 9.1. Inflammatory Bowel Disease
• 9.2. Lupus Erythematosus
• 9.3. Multiple Sclerosis
• 9.4. Psoriasis
• 9.5. Rheumatoid Arthritis
• 9.6. Type 1 Diabetes

10. Autoimmune Disease Therapeutics Market, by Route of Administration

• 10.1. Injectable
  • 10.1.1. Intramuscular
  • 10.1.2. Intravenous
  • 10.1.3. Subcutaneous
• 10.2. Oral

11. Autoimmune Disease Therapeutics Market, by Therapeutic Application

• 11.1. Disease Progression Alteration
• 11.2. Immune System Modulation
• 11.3. Pain Management
• 11.4. Reduction of Inflammation

12. Autoimmune Disease Therapeutics Market, by End-User

• 12.1. Ambulatory Surgical Centers
• 12.2. Hospitals
• 12.3. Research Institutes

13. Autoimmune Disease Therapeutics Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Autoimmune Disease Therapeutics Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Autoimmune Disease Therapeutics Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Abbott Laboratories
  • 16.3.2. AbbVie Inc.
  • 16.3.3. Amgen Inc.
  • 16.3.4. AstraZeneca PLC
  • 16.3.5. Beckman Coulter, Inc.
  • 16.3.6. Bio-Rad Laboratories, Inc.
  • 16.3.7. BioAgilytix Labs, LLC
  • 16.3.8. bioMerieux S.A.
  • 16.3.9. Bristol-Myers Squibb Company
  • 16.3.10. Eli Lilly and Company
  • 16.3.11. Exagen, Inc.
  • 16.3.12. F. Hoffmann-La Roche Ltd.
  • 16.3.13. GlaxoSmithKline PLC
  • 16.3.14. Johnson & Johnson Services, Inc.
  • 16.3.15. Lupin Limited
  • 16.3.16. Merck & Co., Inc.
  • 16.3.17. Novartis AG
  • 16.3.18. Pfizer, Inc.
  • 16.3.19. Sanofi S.A.
  • 16.3.20. Siemens Healthineers AG
  • 16.3.21. Thermo Fisher Scientific Inc.
  • 16.3.22. Trinity Biotech PLC
  • 16.3.23. UCB S.A.
  • 16.3.24. Werfen S.A.